Real-life study of dual therapy based on dolutegravir and ritonavir-boosted darunavir in HIV-1-infected treatment-experienced patients

BACKGROUND: Dual therapy based on dolutegravir and ritonavir-boosted darunavir (DTG/DRV/r) is a combination of well-known drugs with a high genetic barrier to HIV resistance. METHOD: A retrospective analysis of all HIV-1 infected treatment-experienced patients who switched to DTG/DRV/r from May 2014...

Descripción completa

Detalles Bibliográficos
Autores principales: Jabłonowska, Elżbieta, Siwak, Ewa, Bociąga-Jasik, Monika, Gąsiorowski, Jacek, Kalinowska, Anna, Firląg Burkacka, Ewa, Wójcik-Cichy, Kamila, Piątek, Anna, Cielniak, Iwona, Horban, Andrzej
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336297/
https://www.ncbi.nlm.nih.gov/pubmed/30653541
http://dx.doi.org/10.1371/journal.pone.0210476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336297/
https://www.ncbi.nlm.nih.gov/pubmed/30653541
http://dx.doi.org/10.1371/journal.pone.0210476

Ejemplares similares